Not an actual patient.

BAVENCIO was studied in 700 patients with advanced bladder cancerCancer that forms in tissues of the bladder, like urothelial cancer.tooltip-image that did not progress after platinum-containing chemotherapy (PCC)A type of chemotherapy that uses the metal, platinum, to kill cancer cells.

To be part of the study, patients had to:

  • Have advanced or metastaticThe spread of cancer cells to other parts of the body.tooltip-image bladder cancer
  • Have at least 1 lesion, or damaged area, that was evaluated
  • Have gone through 4 to 6 cycles of PCC
  • Showed they are physically functional
  • Not had any autoimmune diseases (conditions where the immune systemA network of cells, tissues, and organs to help your body fight infections and diseases.tooltip-image attacks your own body) or need a treatment that weakened their immune system

The study measured overall survivalThe length of time from the date of diagnosis or the start of treatment that the patients are still alive.tooltip-image, or the total time that patients lived after

starting in the trial. Patients were given either: 

  • BAVENCIO and supportive careCare that is given to people to help improve their quality of life during an illness.tooltip-image (350 patients)
  • Only supportive care (350 patients)

Supportive care for advanced bladder cancer may have included antibiotics to kill bacteria, nutritional support for food and energy, hydration to get enough water, and pain management.

In the main results of the study:

BAVENCIO plus supportive care helped some patients live longer than those on supportive care alone.

Not actual patients.

Patients on BAVENCIO plus supportive care lived for a medianThe number that appears as the middle value of a set of measurements.tooltip-image* of 7.1 months longer than patients on supportive care alone.

The median overall survival for BAVENCIO plus the best supportive care was 21.4 months and 14.3 months for the best supportive care alone.

*The median number is in the middle of all the results. Half of the people who had BAVENCIO and supportive care lived for more than 21.4 months, and half lived for less.

Risk of Death
reduction in risk of death

BAVENCIO plus supportive care decreased the risk of death by 31% compared with supportive care alone in patients who are stable after receiving PCC.

BAVENCIO plus supportive care decreased the risk of death by 31% compared with supportive care alone in patients who are stable after receiving PCC.

In the extended study results:

BAVENCIO showed consistent results when the study kept track of patients for over 3 years.

BAVENCIO® Long Term Data
BAVENCIO®-Long-Term-Data

Patients who had BAVENCIO plus supportive care lived for a median of 8.8 months longer than those who had only supportive care.

Doctor Discussion Guide

Doctor Discussion Guide

Talk to your doctor about BAVENCIO today. We have a guide that can help you ask questions to see if BAVENCIO is right for you. Be a part of the team that is taking care of your health.

"I put my faith in my doctors and knew it was time to make a plan."

— Peter, a real patient on BAVENCIO